论文部分内容阅读
目的:评价厄贝沙坦与辛伐他汀联用以及缬沙坦与贝那普利联用的两种方法治疗糖尿病肾病(DN)患者的临床疗疗效。方法:选取2012年2月—2015年2月间收治的DN患者137例作为研究对象;按照患者自愿原则将其分为研究组75例和对照组62例,其中研究组患者均给予厄贝沙坦与辛伐他汀联用治疗,对照组患者均给予缬沙坦与贝那普利联用治疗,比较两组患者治疗后的临床疗效。结果:治疗前,两组患者的各项生化指标均明显下降(P<0.05);研究组患者UARE、β2-MG、Hb Alc和LDL水平显著低于对照组(P<0.05),临床治疗的总有效率为90.67%显著高于对照组为85.48%(P<0.05);不良反应的发生率为4.00%显著低于对照组为12.90%(P<0.05)。结论:临床治疗DN患者时首选厄贝沙坦与辛伐他汀联用治疗,其各项生化指标和不良反应的发生率均优于缬沙坦与贝那普利的治疗。
Objective: To evaluate the clinical efficacy of irbesartan in combination with simvastatin and valsartan in combination with benazepril in the treatment of patients with diabetic nephropathy (DN). Methods: A total of 137 patients with DN were enrolled from February 2012 to February 2015. The patients were divided into study group (75 cases) and control group (62 cases) according to the voluntary principle of patients. Among them, Tan combined with simvastatin treatment, patients in the control group were given valsartan combined with benazepril treatment, the clinical efficacy of the two groups were compared. Results: The biochemical indexes of two groups were significantly decreased before treatment (P <0.05). The levels of UARE, β2-MG, Hb Alc and LDL in study group were significantly lower than those in control group (P <0.05) The total effective rate was 90.67%, which was significantly higher than that of the control group (85.48%, P <0.05). The incidence of adverse reactions was 4.00%, significantly lower than that of the control group (12.90%, P <0.05). CONCLUSION: The combination of irbesartan and simvastatin is the best choice for clinical treatment of DN patients. The biochemical indexes and the incidence of adverse reactions are superior to valsartan and benazepril treatment.